Viral Vector Manufacturing - Global Strategic Business Report

Report
402 Pages
March 2024
Region: Global
Global Industry Analysts, Inc
ID: 4806192

The global market for Viral Vector Manufacturing is estimated at US$788 Million in 2023 and is projected to reach US$2.5 Billion by 2030, growing at a CAGR of 15.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Key Insights:

Market Growth: Understand the significant growth trajectory of the Retroviral Vectors segment, which is expected to reach US$935.6 Million by 2030 with a CAGR of 15.6%. The Adenoviral Vectors segment is also set to grow at 16% CAGR over the next 8 years.
Regional Analysis: Gain insights into the U.S. market, estimated at $477 Million in 2023, and China, forecasted to grow at an impressive 18.5% CAGR to reach $107.9 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

Detailed Market Analysis: Access a thorough analysis of the Global Viral Vector Manufacturing Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Viral Vector Manufacturing Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

How is the Global Viral Vector Manufacturing Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?

Report Features:

Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of major players such as Bayer AG, Janssen Pharmaceuticals, Inc., Akron Biotech, and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 80 Featured):

Bayer AG
Janssen Pharmaceuticals, Inc.
Akron Biotech
GeneCopoeia, Inc.
Aldevron
GenScript Biotech Corporation
DNA TwoPointO Inc. (dba ATUM)
Genelux Corporation
Cell and Gene Therapy Catapult
ID Pharma Co., Ltd.
Global Life Sciences Solutions USA LLC (Cytiva)
Algenex
BioFactura
Delphi Genetics
FinVector OY

MarketGlass Platform

Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

An Introduction to Viral Vector Manufacturing
Applications of Viral Vectors
Types of Viral Vectors
Global Viral Vector Manufacturing Market: Prospects & Outlook
Competition
Recent Market Activity
Viral Vector Manufacturing - Global Key Competitors Percentage Market Share in 2023 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Increasing Prevalence of Infectious Diseases, Genetic Disorders & Cancers Drives Market
Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
Life Expectancy at Age 60 and 80 Years: (2010-2015), (2020-2025) & (2045-2050)
Gene Therapy Emerges as a Major Therapeutic Approach for InheriTable and Acquired Diseases, Spurring Market Prospects
Viral Vectors Lead the Gene Therapy Market
Adeno-Associated Virus Vectors: A Leading Platform for Gene Therapy
Lentiviral Vectors Witness Increased Interest for Gene Therapy
Funding Support for Gene Therapy Development Presents Market Opportunities
Complexity in Viral Vector Production for Gene therapies
Amidst Rising Cancer Incidence, Focus on Viral Vector-based Gene Therapies to Boost Market
Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2023
Number of New Cancer Cases and Deaths (in Million) by Region for 2023
Engineered and Natural Oncolytic Viral Vectors: A Key Development in Viral Vector-based Cancer Therapy
Growing Threat Posed by Infectious Diseases Drives Focus onto Vector Viral-based Therapies & Vaccines
Infectious Diseases Remain Major Cause of Death in Under Developed Regions: Breakdown of Leading Causes of Death in Sub-Saharan Africa (in %)
Infectious Diseases Related Mortality High Among Children Below 5 Years: Breakdown of Leading Causes of Death in Children Below 5 Years (in %)
Rising Significance of Viral Vectors in New Vaccine Development
Adenovirus-based Vaccines: Evolution Over the Years
Viral Vector Emerges as a Next-Gen Platform for COVID-19 Vaccines Development
Replicating and Non-Replicating Viral Vector-Based Vaccines
Market to Benefit from the Emergence of New Technologies to Manufacture Viral Vectors
New Trends for Optimizing Workflow Using Viral Vectors
Production Workflow & Viral Vectors
Closed-System-Adherent Culture of Cells: Recent Advances
Limitations in Viral Vector Manufacturing Impact Market
Innovations & Collaborations: Essential to Resolve Challenges Facing Large-Scale GMP Viral Vector Manufacturing

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 2: World Historic Review for Viral Vector Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2022 and % CAGR
Table 3: World 14-Year Perspective for Viral Vector Manufacturing by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2016, 2024 & 2030
Table 4: World Recent Past, Current & Future Analysis for Retroviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 5: World Historic Review for Retroviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2022 and % CAGR
Table 6: World 14-Year Perspective for Retroviral Vectors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2024 & 2030
Table 7: World Recent Past, Current & Future Analysis for Adenoviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 8: World Historic Review for Adenoviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2022 and % CAGR
Table 9: World 14-Year Perspective for Adenoviral Vectors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2024 & 2030
Table 10: World Recent Past, Current & Future Analysis for Adeno-associated Viral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 11: World Historic Review for Adeno-associated Viral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2022 and % CAGR
Table 12: World 14-Year Perspective for Adeno-associated Viral Vectors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2024 & 2030
Table 13: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 14: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2022 and % CAGR
Table 15: World 14-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2024 & 2030
Table 16: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 17: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2022 and % CAGR
Table 18: World 14-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2024 & 2030
Table 19: World Recent Past, Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 20: World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2022 and % CAGR
Table 21: World 14-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2024 & 2030
Table 22: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 23: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2022 and % CAGR
Table 24: World 14-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2024 & 2030
Table 25: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 26: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2022 and % CAGR
Table 27: World 14-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2024 & 2030
Table 28: World Recent Past, Current & Future Analysis for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 29: World Historic Review for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2022 and % CAGR
Table 30: World 14-Year Perspective for Pharma & Biopharma Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2024 & 2030
Table 31: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
Table 32: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2022 and % CAGR
Table 33: World 14-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2024 & 2030
Table 34: World Viral Vector Manufacturing Market Analysis of Annual Sales in US$ Thousand for Years 2016 through 2030

III. MARKET ANALYSIS

UNITED STATES

Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)

CANADA

JAPAN

Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)

CHINA

Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)

EUROPE

Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)

FRANCE

Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)

GERMANY

Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)

ITALY

UNITED KINGDOM

Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)

REST OF EUROPE

ASIA-PACIFIC

Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)

REST OF WORLDIV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Bayer AG
Janssen Pharmaceuticals, Inc.
Akron Biotech
GeneCopoeia, Inc.
Aldevron
GenScript Biotech Corporation
DNA TwoPointO Inc. (dba ATUM)
Genelux Corporation
Cell and Gene Therapy Catapult
ID Pharma Co., Ltd.
Global Life Sciences Solutions USA LLC (Cytiva)
Algenex
BioFactura
Delphi Genetics
FinVector OY

Table Information

Report Attribute	Details
No. of Pages	402
Published	March 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 788 Million
Forecasted Market Value ( USD ) by 2030	$ 2500 Million
Compound Annual Growth Rate	15.8%
Regions Covered	Global

PURCHASE OPTIONS

Single User License PDF

1 - 10 User License PDF

Enterprise License PDF

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5238EUR$5,450USD£4,429GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€9953EUR$10,355USD£8,416GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€15715EUR$16,350USD£13,288GBP

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Select Competitors (Total 80 Featured):

MarketGlass Platform

Table of Contents

Companies Mentioned (Partial List)

Table Information

Related Topics

Related Reports

Viral Vector Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Viral Vector and Plasmid DNA Manufacturing Market - Global Forecast to 2028

Viral Vector Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Global Viral Vector Manufacturing Market by Type (Adeno-associated Viral Vectors, Adenoviral Vectors, Lentiviral Vectors), Disease (Cancer, Genetic Disorders, Infectious Diseases), Application - Forecast 2024-2030

Global Viral Vector & Plasmid DNA Manufacturing Market by Type (Plasmid DNA, Viral Vector), Cell Line (In-vitro, In-Vivo), Transfection, Indication, Workflow, Application, End User - Forecast 2024-2030